Tufts releases report on causes of drug development failures

On September 10, 2013, the Tufts Center for the Study of Drug Development released a report concerning the leading causes of failures in drug development. Based on a study of products that entered clinical development from 2000 through 2009, the study found that Phase I failures were linked to commercial reasons almost 41% of the time, while the bulk of Phase II failures could be explained by efficacy issues just over 50% of the time. This study’s results help researchers because, “It is in the interest of drug developers to have new products fail earlier, rather than later, in development, as earlier terminations avoid the costs of larger, more complex studies.” as Joseph A. DiMasi, Tufts CSDD director of economic analysis, explains. To view the full Tufts CSDD report click here.